Detalhe da pesquisa
1.
The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer.
Bioorg Med Chem Lett
; 75: 128951, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36031020
2.
Tricyclic sulfones as potent, selective and efficacious RORγt inverse agonists - Exploring C6 and C8 SAR using late-stage functionalization.
Bioorg Med Chem Lett
; 30(23): 127521, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32882417
3.
Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.
Bioorg Med Chem Lett
; 27(14): 3101-3106, 2017 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28539220
4.
Discovery of highly potent, selective, covalent inhibitors of JAK3.
Bioorg Med Chem Lett
; 27(20): 4622-4625, 2017 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28927786
5.
Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.
Bioorg Med Chem Lett
; 24(24): 5721-5726, 2014 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25453808
6.
Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study.
Lancet Rheumatol
; 5(5): e263-e273, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38251590
7.
Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies.
Anal Bioanal Chem
; 402(3): 1229-39, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22130720
8.
7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.
Bioorg Med Chem Lett
; 21(22): 6646-51, 2011 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21996520
9.
Population Pharmacokinetic Analysis of BMS-986166, a Novel Selective Sphingosine-1-Phosphate-1 Receptor Modulator, and Exposure-Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants.
Clin Pharmacol Drug Dev
; 10(1): 8-21, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33090733
10.
Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.
ACS Med Chem Lett
; 12(5): 827-835, 2021 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34055233
11.
Tricyclic-Carbocyclic RORγt Inverse Agonists-Discovery of BMS-986313.
J Med Chem
; 64(5): 2714-2724, 2021 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33591748
12.
Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.
Bioorg Med Chem Lett
; 20(15): 4395-8, 2010 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20598534
13.
Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening Approach.
ACS Med Chem Lett
; 11(12): 2510-2518, 2020 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335675
14.
Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist.
ACS Med Chem Lett
; 11(6): 1221-1227, 2020 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32551004
15.
Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK.
ACS Med Chem Lett
; 11(11): 2195-2203, 2020 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33214829
16.
Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
Drug Metab Dispos
; 37(6): 1164-71, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19251818
17.
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis.
ACS Med Chem Lett
; 10(3): 306-311, 2019 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30891131
18.
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
J Med Chem
; 62(7): 3228-3250, 2019 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30893553
19.
Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy.
J Med Chem
; 62(21): 9931-9946, 2019 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31638797
20.
Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.
Bioorg Med Chem Lett
; 18(6): 1910-5, 2008 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18291644